本帖最后由 老马 于 2012-1-13 21:20 编辑
+ t% } g+ P9 Q( n4 t
. y+ j2 A# f0 @% d8 e爱必妥和阿瓦斯丁的比较3 T& S: p& m) @8 k
2 V3 K3 |, z9 M( }! W% d9 R& jhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
5 E( K5 f* N% \( L {
2 B! E3 Y& A5 z0 n
' G* S+ x9 }* K) P
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
9 M5 M" u# c, j, @0 |==================================================# V. c$ `" ]9 v& }# H2 a- j
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)( T" m$ f" C, c" }
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point." J( J+ e+ v) o, J; F& [
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
1 q$ U: F d4 o
|